Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Exploring the Phase 3 KEYNOTE-564 clinical trial data of KEYTRUDA (pembrolizumab) in patients with renal cell carcinoma.

Ticker(s): MRK

Who's the expert?

Institution: Self-employed

Board Certified Hematologist and Medical Oncologist in private practice since 2011
treats 25 patients for B-Cell Non-Hodgkin’s Lymphoma, 10 of whom have the diffuse large B-cell lymphoma (DLBCL) subtype

Interview Goal

to discuss the current standard of care and the potential of Merck's KEYTRUDA (pembrolizumab), as an adjuvant therapy for renal cell carcinoma following nephrectomy.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.